ClinicalTrials.gg
CompletedNCT05282004Updated May 10, 2023Results posted

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

A Phase 3 interventional study of SOK583A1 in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz. Completed at 5 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
46th of 66
36 · median 55
Started
2022
with 3 others
Phase 3
18 of 66
1 open now
Registered
52nd of 66
by date
Lead sponsor
3 of 66
Sandoz

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 46th largest by enrollment, is one of 4 that started in 2022, is one of 18 in phase 3, and was the 52nd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.

Read the detailed description

Subjects with nAMD received a single dose of study treatment (2 mg SOK583 in 0.05 mL) in line with the Eylea USPI, which recommends a dose of 2 mg aflibercept (0.05 mL) administered by IVT injection. Only subjects already under IVT Eylea treatment and hence familiar with the IVT procedure were eligible for the study. Administration of the study treatment was embedded into their routine treatment scheme.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (nAMD)

Keywords

  • Open label study,
  • intravitreal injection,
  • biosimilar,
  • aflibercept,
  • vial kit
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 50 years of age at baseline
  • Patients diagnosed with nAMD (uni- or bilateral)
  • Patients already under IVT Eylea treatment (last injection of the induction period or maintenance phase)
  • Willing and able to comply with all study procedures, and be likely to complete the study
  • Signed must be obtained before any assessment is performed

Exclusion criteria

Exclusion Criteria:

  • Active, suspected or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or associated uveitis or endophthalmitis
  • Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as IOP ≥ 26 mmHg, despite treatment with anti-glaucomatous medication)
  • History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of product
  • Visual acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness
  • Topical ocular administered for at least 30 consecutive days within 3 months prior to screening
  • Systemic treatment with long-acting corticosteroids (more than 10 mg prednisolone equivalent) within 3 months prior to screening Current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol
  • Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months
  • Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment
  • Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening)
  • Participants who do not comply with the local COVID-19 regulations of the study site
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    SOK583A1

    SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)

    Drug: SOK583A1

Interventions

  • SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular Treatment Emergent Adverse Events

    Number of participants with ocular treatment emergent adverse events were reported.

    Time frame: 31 days

  2. Number of Participants With Non-ocular Treatment Emergent Adverse Events

    Number of participants with non-ocular treatment emergent adverse events were reported.

    Time frame: 31 days

07

Results

Posted May 10, 2023

Participant flow

The study was conducted at 5 study sites in the USA.

Participant flow — Overall Study
MilestoneSOK583A1 40 mg/mL
Started36
Completed34
Not completed2
Withdrew: Adverse event2

Outcome measures

PrimaryNumber of Participants With Ocular Treatment Emergent Adverse Events

Number of participants with ocular treatment emergent adverse events were reported.

Time frame:
31 days
Reported as:
Count of participants · Participants
Number of Participants With Ocular Treatment Emergent Adverse Events
ParticipantsSOK583A1 40 mg/mL
Number of Participants With Ocular Treatment Emergent Adverse Events16
PrimaryNumber of Participants With Non-ocular Treatment Emergent Adverse Events

Number of participants with non-ocular treatment emergent adverse events were reported.

Time frame:
31 days
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular Treatment Emergent Adverse Events
ParticipantsSOK583A1 40 mg/mL
Number of Participants With Non-ocular Treatment Emergent Adverse Events3

Adverse events

Collected over Adverse events were collected throughout the study for 31 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOK583A1 40 mg/mL0/36 (0%)2/36 (5.6%)17/36 (47.2%)
Most frequent serious events
Most frequent serious events
EventSOK583A1 40 mg/mL
CystitisInfections and infestations1/36
ArthralgiaMusculoskeletal and connective tissue disorders1/36
Most frequent other events
Most frequent other events
EventSOK583A1 40 mg/mL
Intraocular pressure increasedInvestigations15/36
Conjunctival haemorrhageEye disorders2/36
Vitreous floatersEye disorders1/36
COVID-19Infections and infestations1/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)SOK583A1 40 mg/mL
Mean80.9 ± 8.45
Sex: Female, Male
Sex: Female, Male(Participants)SOK583A1 40 mg/mL
Female20
Male16
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SOK583A1 40 mg/mL
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White36
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Sandoz Investigational Site
    Poway, California 92064, United States
  • Sandoz Investigational Site
    Marietta, Georgia 30060, United States
  • Sandoz Investigational Site
    Oak Forest, Illinois 60452, United States
  • Sandoz Investigational Site
    Liverpool, New York 13088, United States
  • Sandoz Investigational Site
    Lynchburg, Virginia 24502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2022, 3 months.

Results were first posted in May 2023, 8 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 3 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 16, 2022
StartActual
May 16, 2022
Primary completionActual
Sep 7, 2022
CompletionActual
Sep 7, 2022
Results first posted
May 10, 2023
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05282004
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
May 16, 2022
Primary completion
Sep 7, 2022
Completion
Sep 7, 2022
Results posted
May 10, 2023
Last update
May 10, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion